CytomX Therapeutics Inc.
CTMX | NASDAQ
$2.78
+$0.02 (+0.72%)
Sep 22, 2026, 9:30 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 76.2M | 138.1M | 101.21M | 53.16M | 37.31M | 68.43M |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | 76.2M | 138.1M | 101.21M | 53.16M | 37.31M | 68.43M |
Operating Income | -22.36M | 25M | -6.48M | -101.34M | -116.04M | -80.54M |
Interest Income | 5.21M | 7.14M | 9.84M | 1.68M | 255K | 1.84M |
Pretax Income | -17.13M | 32.09M | 3.32M | -99.32M | -115.87M | -50.91M |
Net Income | -17.37M | 31.87M | -569K | -99.32M | -115.87M | -64.82M |
Selling & General & Admin | 29.84M | 29.73M | 30.02M | 42.85M | 39.16M | 36.03M |
Research & Development | 68.73M | 83.38M | 77.68M | 111.65M | 114.19M | 112.94M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 98.57M | 113.11M | 107.7M | 154.5M | 153.35M | 148.97M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 98.57M | 113.11M | 107.7M | 154.5M | 153.35M | 148.97M |
Income Tax Expense | 238K | 224K | 3.89M | n/a | n/a | 13.91M |
Shares Outstanding (Basic) | 137.94M | 84.44M | 73.81M | 65.74M | 64.15M | 46.15M |
Shares Outstanding (Diluted) | 137.94M | 84.75M | 73.81M | 65.74M | 64.15M | 46.15M |
EPS (Basic) | -0.15 | 0.38 | -0.01 | -1.48 | -1.26 | -0.71 |
EPS (Diluted) | -0.15 | 0.38 | -0.01 | -1.48 | -1.26 | -0.71 |
EBITDA | -15.75M | 33.86M | 5.5M | -96.87M | -113.16M | -77.97M |
EBIT | -17.13M | 32.09M | 3.32M | -99.32M | -115.87M | -80.54M |
Depreciation & Amortization | 1.38M | 1.77M | 2.18M | 2.44M | 2.71M | 2.57M |
Add to Watchlist
Select watchlists to add or remove CTMX